Professor of Medicine, University S Fla College of Medicine
Hematology
Dr. Alan F. List, MD
|
|
Give Review
Alan List is an expert in the field of Hematology. He went to medical school at Perelman School of Medicine at the University of Pennsylvania. He over the years received 1 awards: "Super Doctor". Alan F. List is also a published doctor. He has 43 publication published. The most recent publication is: Autoimmune Diseases and Myelodysplastic Syndromes. He is registered with Medicare.
Publications
- Outcomes of patients with Myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
- Autoimmune Diseases and Myelodysplastic Syndromes.
- Comparing the prognostic value of risk stratifying models for patients with lower-risk Myelodysplastic syndromes: Is one model better?
- Reduced DOCK4 expression leads to erythroid dysplasia in Myelodysplastic syndromes.
- TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) Myelodysplastic syndromes.
- Short- and Long-Term Benefits of Lenalidomide Treatment in Patients With Lower-Risk del(5q) Myelodysplastic Syndromes.
- Impact of TP53 mutation variant allele frequency on phenotype and outcomes in Myelodysplastic syndromes.
- Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic Cell transplantation: a single-center experience and a review of the literature.
- A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.
- WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
- Update on the pharmacotherapy for Myelodysplastic syndromes.
- A phase II multicenter rabbit anti-thymocyte globulin trial in patients with Myelodysplastic syndromes identifying a novel model for response prediction.
- SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed Acute myeloid leukaemia.
- Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) Myelodysplastic syndromes.
- Phase II clinical study of erlotinib for treatment of Myelodysplastic syndromes.
- The clinical management of chronic myelomonocytic Leukemia.
- Pre-transplant 5-azacitidine in high-risk Myelodysplastic syndrome.
- Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodys...
- Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in Acute myeloid leukemia from myelodysplastic syndrome after azanucleosid...
- Deletion 5q MDS: Molecular and therapeutic implications.
- High rate of uncaptured Myelodysplastic syndrome cases and an improved method of case ascertainment.
- Extended survival and reduced risk of AML progression in erythroid responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
- Multikinase inhibitors for treating high-risk Myelodysplastic syndromes: can this be brought into clinical practice?
- Poor outcome of patients with Myelodysplastic syndrome after azacitidine treatment failure.
- TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
- Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.
- Phase I clinical trial of oral rigosertib in patients with Myelodysplastic syndromes.
- STAT3-mutations indicate the presence of subclinical T Cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.
- Outcome of azacitidine treatment in patients with therapy-related Myeloid neoplasms with assessment of prognostic risk stratification models.
- GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic Leukemia.
- Validation of the revised international prognostic scoring system in treated patients with Myelodysplastic syndromes.
- B-Lymphoblastic Leukemia/Lymphoma Associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : Rare Case and Review of the Literature.
- Naive T-Cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.
- Randomized, dose-escalation study of the p38? MAPK inhibitor SCIO-469 in patients with Myelodysplastic syndrome.
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in Myelodysplastic syndrome with chromosome 5q deletion.
- Altered naive and memory CD4+ T-Cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.
- The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in Myelodysplastic syndromes.
- Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in Myelodysplastic syndrome progenitors.
- PP2A: The Achilles Heal in MDS with 5q Deletion.
- Validation of the IPSS-R in lenalidomide-treated, lower-risk Myelodysplastic syndrome patients with del(5q).
Schools
University Of Pennsylvania School Of Medicine
Intern Good Samaritan Medical Center Phoenix AzInternal Medicine
Good Samaritan Regional Med Center
Fellow Vanderbilt University Medical Center Nashville TnHematology
Vanderbilt University Med Center
Bs Bucknell University Lewisburg Pa
Ma Bucknell University Lewisburg Pa
Procedures Preformed
- Bone Marrow Transplant
- Plasmapheresis
Conditions Treated
- Acute Myeloid Leukemia
- Adrenal Gland Cancer
- Basal Cell Carcinoma
- Bone Marrow Disorders
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
Vanderbilt University -
Banner Good Samaritan Medical Center -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1710908314 | |
| NPPES Provider LastName | LIST | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 90.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710908314 |
| Last Name Of The Provider | LIST |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
Dr. Reza Setoodeh, MD |
|
Dr. Kenneth H. Shain, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ron D. Schiff, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Claudio Anasetti, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Marcie R. Tomblyn, MD |
|
|
Dr. Christopher B. George, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rafael W. Blanco, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Teresa L. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Asmita Mishra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saqib Razzaque, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Shields, MD |
|
|
Dr. David E. Jones Jr., MD |
|
|
Dr. Gerold Bepler, MD |